VISTIN PHARMA ASA (VISTN.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:VISTN - NO0010734122 - Common Stock
20.6 NOK
+0.1 (+0.49%)
We assign a fundamental rating of 5 out of 10 to VISTN. VISTN was compared to 54 industry peers in the Pharmaceuticals industry. VISTN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VISTN has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
VISTN had positive earnings in the past year.
In the past year VISTN had a positive cash flow from operations.
In multiple years VISTN reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: VISTN reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 18.05%, VISTN belongs to the top of the industry, outperforming 96.30% of the companies in the same industry.
The Return On Equity of VISTN (25.86%) is better than 72.22% of its industry peers.
VISTN's Return On Invested Capital of 21.14% is amongst the best of the industry. VISTN outperforms 87.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.05% | ||
| ROE | 25.86% | ||
| ROIC | 21.14% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of VISTN (16.84%) is better than 68.52% of its industry peers.
In the last couple of years the Profit Margin of VISTN has declined.
VISTN has a Operating Margin (21.56%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of VISTN has grown nicely.
VISTN has a Gross Margin (66.38%) which is comparable to the rest of the industry.
VISTN's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.56% | ||
| PM (TTM) | 16.84% | ||
| GM | 66.38% |
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VISTN is creating value.
There is no outstanding debt for VISTN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VISTN has an Altman-Z score of 6.92. This indicates that VISTN is financially healthy and has little risk of bankruptcy at the moment.
VISTN's Altman-Z score of 6.92 is amongst the best of the industry. VISTN outperforms 90.74% of its industry peers.
VISTN has a debt to FCF ratio of 0.56. This is a very positive value and a sign of high solvency as it would only need 0.56 years to pay back of all of its debts.
VISTN has a Debt to FCF ratio of 0.56. This is amongst the best in the industry. VISTN outperforms 92.59% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that VISTN is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.14, VISTN belongs to the best of the industry, outperforming 81.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 0.56 | ||
| Altman-Z | 6.92 |
ROIC/WACC2.48
WACC8.52%
2.3 Liquidity
A Current Ratio of 1.73 indicates that VISTN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.73, VISTN is in the better half of the industry, outperforming 68.52% of the companies in the same industry.
A Quick Ratio of 0.94 indicates that VISTN may have some problems paying its short term obligations.
VISTN has a Quick ratio (0.94) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
VISTN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.41%, which is quite good.
Measured over the past years, VISTN shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.03% on average per year.
The Revenue has been growing slightly by 3.23% in the past year.
VISTN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.56% yearly.
EPS 1Y (TTM)11.41%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%-3.59%
Revenue 1Y (TTM)3.23%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%10.92%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 11.98, the valuation of VISTN can be described as very reasonable.
Based on the Price/Earnings ratio, VISTN is valued a bit cheaper than the industry average as 77.78% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.29. VISTN is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.98 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VISTN indicates a somewhat cheap valuation: VISTN is cheaper than 79.63% of the companies listed in the same industry.
85.19% of the companies in the same industry are more expensive than VISTN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.07 | ||
| EV/EBITDA | 7.75 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
VISTN has a Yearly Dividend Yield of 6.31%, which is a nice return.
Compared to an average industry Dividend Yield of 2.90, VISTN pays a better dividend. On top of this VISTN pays more dividend than 94.44% of the companies listed in the same industry.
VISTN's Dividend Yield is rather good when compared to the S&P500 average which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.31% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
101.97% of the earnings are spent on dividend by VISTN. This is not a sustainable payout ratio.
DP101.97%
EPS Next 2YN/A
EPS Next 3YN/A
OSL:VISTN (12/10/2025, 12:18:06 PM)
20.6
+0.1 (+0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.3%
Inst Owner ChangeN/A
Ins Owners5.62%
Ins Owner ChangeN/A
Market Cap913.40M
Revenue(TTM)451.83M
Net Income(TTM)76.10M
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.31% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP101.97%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.98 | ||
| Fwd PE | N/A | ||
| P/S | 2.02 | ||
| P/FCF | 12.07 | ||
| P/OCF | 9.74 | ||
| P/B | 3.1 | ||
| P/tB | 3.1 | ||
| EV/EBITDA | 7.75 |
EPS(TTM)1.72
EY8.35%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.71
FCFY8.28%
OCF(TTM)2.12
OCFY10.27%
SpS10.19
BVpS6.64
TBVpS6.64
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.05% | ||
| ROE | 25.86% | ||
| ROCE | 30.77% | ||
| ROIC | 21.14% | ||
| ROICexc | 21.27% | ||
| ROICexgc | 21.27% | ||
| OM | 21.56% | ||
| PM (TTM) | 16.84% | ||
| GM | 66.38% | ||
| FCFM | 16.74% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
F-Score7
Asset Turnover1.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 0.56 | ||
| Debt/EBITDA | 0.36 | ||
| Cap/Depr | 92.47% | ||
| Cap/Sales | 4.02% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 80.15% | ||
| Profit Quality | 99.4% | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | 6.92 |
F-Score7
WACC8.52%
ROIC/WACC2.48
Cap/Depr(3y)280.38%
Cap/Depr(5y)338.81%
Cap/Sales(3y)11.99%
Cap/Sales(5y)13.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.41%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%-3.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.23%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%10.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.61%
EBIT growth 3Y36.89%
EBIT growth 5Y38.44%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.44%
FCF growth 3YN/A
FCF growth 5Y158.58%
OCF growth 1Y16.97%
OCF growth 3Y99.03%
OCF growth 5Y41.62%
VISTIN PHARMA ASA / VISTN.OL FAQ
What is the fundamental rating for VISTN stock?
ChartMill assigns a fundamental rating of 5 / 10 to VISTN.OL.
What is the valuation status of VISTIN PHARMA ASA (VISTN.OL) stock?
ChartMill assigns a valuation rating of 4 / 10 to VISTIN PHARMA ASA (VISTN.OL). This can be considered as Fairly Valued.
Can you provide the profitability details for VISTIN PHARMA ASA?
VISTIN PHARMA ASA (VISTN.OL) has a profitability rating of 5 / 10.
Can you provide the financial health for VISTN stock?
The financial health rating of VISTIN PHARMA ASA (VISTN.OL) is 7 / 10.
How sustainable is the dividend of VISTIN PHARMA ASA (VISTN.OL) stock?
The dividend rating of VISTIN PHARMA ASA (VISTN.OL) is 5 / 10 and the dividend payout ratio is 101.97%.